Clinical application of high-LET radiotherapy combined with immunotherapy in malignant tumors

Abstract

The superior physical and biological properties of high linear energy transfer (LET), as opposed to traditional low-LET rays, underscore the advantage of proton therapy (PRT) and carbon ion radiotherapy (CIRT) are better than traditional photon radiotherapy (XRT). With the advancements in science, an increasing number of hospitals have introduced new technologies. However, radiotherapy is primarily used for local treatment, which means that if the tumor has metastasized to distant sites, it is often necessary to combine it with systemic therapies such as immunotherapy. In recent years, the combination of high-LET radiotherapy and immunotherapy has emerged as a promising treatment option in oncology and many studies have confirmed its efficacy for both local and distant metastases. In this review, we summarize the effects of PRT and CIRT on the immune system in detail, followed by an introduction to preclinical and clinical studies of PRT and CIRT in combination with immune checkpoint inhibitor (ICIs) therapy. We also briefly introduce some preclinical studies on CIRT in combination with dendritic cells (DCs) and Treg inhibitor therapies.

Keywords

carbon ion radiotherapy / high linear energy transfer / immunotherapy / malignant tumor / photon radiotherapy / proton therapy

References

[1] LiuY, DongY, KongL, Shi F, ZhuH, YuJ. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018;11(1):104.

[2] PointerKB, Pitroda SP, WeichselbaumRR. Radiotherapy and immunotherapy: open questions and future strategies. Trends Cancer. 2022;8(1):9-20.

[3] KroezeSGC, PavicM, StellamansK, et al. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol. 2023;24(3):e121-e132.

[4] NickoloffJA, SharmaN, TaylorL. Clustered DNA Double-Strand Breaks: Biological Effects and Relevance to Cancer Radiotherapy. Genes (Basel). 2020;11(1):99.

[5] ElbersJBW, GunschPA, DebetsR, et al. HYpofractionated, dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma: study protocol of the phase I HYDRA trial. BMC Cancer. 2023;23(1):541.

[6] WangX, van Rossum PSN, ChuY, et al. Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Comprehensive Analysis of Randomized Phase 2B Trial of Proton Beam Therapy Versus Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024;118(2):368-377.

[7] KimN, ShinJ, AhnSH, et al. Reduced radiation exposure to circulating blood cells in proton therapy compared with X-ray therapy in locally advanced lung cancer: Computational simulation based on circulating blood cells. Front Oncol. 2023;13:1119173.

[8] McCullumL, ShinJ, XingS, et al. Predicting Severity of Radiation Induced Lymphopenia in Individual Proton Therapy Patients for Varying Dose Rate and Fractionation Using Dynamic 4-Dimensional Blood Flow Simulations. Int J Radiat Oncol Biol Phys. 2023;116(5):1226-1233.

[9] NielsenS, Bassler N, GrzankaL, et al. Proton scanning and X-ray beam irradiation induce distinct regulation of inflammatory cytokines in a preclinical mouse model. Int J Radiat Biol. 2020;96(10):1238-1244.

[10] NielsenS, SitarzMK, SinhaPM, et al. Using immunotherapy to enhance the response of a C3H mammary carcinoma to proton radiation. Acta Oncol. 2023;62(11):1581-1586.

[11] ChenMF, ChenPT, HsiehCC, Wang CC. Effect of Proton Therapy on Tumor Cell Killing and Immune Microenvironment for Hepatocellular Carcinoma. Cells. 2023;12(2):332.

[12] HuY, ParisS, SahooN, et al. Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection. JCI Insight. 2023;8(12):e167749.

[13] CarrasquillaM, PaudelN, CollinsBT, et al. High-Risk Non-Small Cell Lung Cancer Treated With Active Scanning Proton Beam Radiation Therapy and Immunotherapy. Adv Radiat Oncol. 2022;8(2):101125.

[14] NakamuraM, Kageyama SI, HirataH, et al. Detection of Pretreatment Circulating Tumor DNA Predicts Recurrence after High-Dose Proton Beam Therapy for Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023;116(5):1085-1090.

[15] SuCW, HouMM, HuangPW, et al. Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma. Am J Cancer Res. 2022;12(4):1606-1620.

[16] MaMW, WangZS, LiHZ, et al. Breaking barriers: Stereotactic ablative proton and photon radiation therapy for renal cell carcinoma with extensive metastases: A case report. Med Dosim. 2024;49(1):41-45.

[17] WebbMJ, BreenWG, LaackNN, Leventakos K, CampianJL, SenerU. Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: a case report. CNS Oncol. 2023;12(3):CNS101.

[18] Yegya-RamanN, BermanAT, CiunciCA, et al. Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys.

[19] Janopaul-NaylorJR, Cao Y, McCallNS, et al. Definitive intensity modulated proton re-irradiation for lung cancer in the immunotherapy era. Front Oncol. 2023;12:1074675.

[20] KimH, ParkS, JungHA, et al. Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Cancer Res Treat. 2023;55(4):1104-1112.

[21] HuW, PeiY, NingR, et al. Immunomodulatory effects of carbon ion radiotherapy in patients with localized prostate cancer. J Cancer Res Clin Oncol. 2023;149(8):4533-4545.

[22] ZhouH, TuC, YangP, et al. Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice. Oncoimmunology. 2022;11(1):2057892.

[23] ChiblakS, TangZ, LemkeD, et al. Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche. JCI Insight. 2019;4(2):e123837.

[24] WangJ, DaiZ, MiaoY, et al. Carbon ion (¹²C⁶⁺) irradiation induces the expression of Klrk1 in lung cancer and optimizes the tumor microenvironment based on the NKG2D/NKG2D-Ls pathway. Cancer Lett.

[25] KönigL, Hommertgen A, OrschiedtL, et al. Influence of photon, proton and carbon ion irradiation on differentiation, maturation and functionality of dendritic cells. Front Biosci (Schol Ed). 2022;14(1):2.

[26] HuangY, DongY, ZhaoJ, Zhang L, KongL, LuJJ. Comparison of the effects of photon, proton and carbon-ion radiation on the ecto-calreticulin exposure in various tumor cell lines. Ann Transl Med. 2019;7(20):542.

[27] TakahashiY, YasuiT, MinamiK, et al. Carbon ion irradiation enhances the antitumor efficacy of dual immune checkpoint blockade therapy both for local and distant sites in murine osteosarcoma. Oncotarget. 2019;10(6):633-646.

[28] OnishiM, Okonogi N, OikeT, et al. High linear energy transfer carbon-ion irradiation increases the release of the immune mediator high mobility group box 1 from human cancer cells. J Radiat Res. 2018;59(5):541-546.

[29] RanJ, WangJ, DaiZ, et al. Irradiation-Induced Changes in the Immunogenicity of Lung Cancer Cell Lines: Based on Comparison of X-rays and Carbon Ions. Front Public Health. 2021;9:666282.

[30] HelmA, Tinganelli W, SimonielloP, et al. Reduction of Lung Metastases in a Mouse Osteosarcoma Model Treated With Carbon Ions and Immune Checkpoint Inhibitors. Int J Radiat Oncol Biol Phys. 2021;109(2):594-602.

[31] HuangQ, HuJ, ChenL, et al. Carbon ion radiotherapy combined with immunotherapy: synergistic anti-tumor efficacy and preliminary investigation of ferroptosis. Cancer Immunol Immunother. 2023;72(12):4077-4088.

[32] HartmannL, OsenW, EichmüllerOL, et al. Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model. Cancer Lett. 2022;550:215928.

[33] HuangY, HuangQ, ZhaoJ, et al. The Impacts of Different Types of Radiation on the CRT and PDL1 Expression in Tumor Cells Under Normoxia and Hypoxia. Front Oncol. 2020;10:1610.

[34] AndoK, FujitaH, HosoiA, et al. Intravenous dendritic cell administration enhances suppression of lung metastasis induced by carbon-ion irradiation. J Radiat Res. 2017;58(4):446-455.

[35] MaL, Sakamoto Y, AndoK, et al. Th Balance-Related Host Genetic Background Affects the Therapeutic Effects of Combining Carbon-Ion Radiation Therapy With Dendritic Cell Immunotherapy. Int J Radiat Oncol Biol Phys. 2022;112(3):780-789.

[36] CavalieriS, VitoloV, BarcelliniA, et al. Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC). Future Oncol. 2023;19(3):193-203.

[37] CavalieriS, RonchiS, BarcelliniA, et al. Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma. Radiother Oncol. 2021;164:1-5.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.